免责声明
Metascreen^®是康盛人生集团的注册商标。Metascreen^®品牌旗下的筛选试验是通过康盛人生（香港）有限公司（Cordlife Hong Kong, CLHK）进行。 CLHK致力于为新生儿提供快与准确的代谢筛查。此公司已设立质量管理体系，以确保能达到最准确的检查结果。正如任何实验室测试，由于各种原因，包括但不限于病人在采集样本时的年龄，病人的健康状态，样本质量和其他因素等，获得假阳性或假阴性结果不能完全避免。因此，患疾病的可能性不应该仅根据检查结果而被排除。如有观察到的病征或症状，应马上让专业医生跟进。

参考:
1) Evaluation of the 18-month "Pilot Study of Newborn Screening for Inborn Errors of Metabolism" in Hong Kong. HK J Paediatric (New Series). 2020;25:16-22
2) Michael J. Laboratory Medicine Practice Guidelines. Follow-up Testing for Metabolic Diseases Identified by Expanded Newborn Screening Using Tandem Mass Spectrometry. The National Academy of Clinical Biochemistry. 2009
3) Based on internal data, as of June 2020.
4) D. Matern, K. Raymond, S. Tortorelli, et al. Improving NBS Performance: The Mayo Clinic Experience Report.
5) Inborn Errors Of Metabolism (IEM). MyHealthh Kementerian Kesihatan Malaysia Website. http://www.myhealth.gov.my/en/inborn-errors-of-metabolism/. Accessed April 2020.